

23rd January, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001
BSE Symbol: INNOVACAP
BSE Scrip Code: 544067

To,
National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, "G" Block
Bandra-Kurla Complex
Bandra (E), Mumbai - 400051
NSE Symbol: INNOVACAP

Dear Sir/Madam,

Subject: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release issued by the Company on the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31st December, 2025.

The Press Release will be available on the website of the Company at <https://www.innovacaptab.com>.

This is for your information and record.

Thanking you,

Yours faithfully,
For **Innova Captab Limited**

Neeharika Shukla
Company Secretary and Compliance Officer

Encl.: As above

INNOVA CAPTAB LIMITED
Press Release
Performance Review of Q3 and 9M FY26

Innova Captab Limited reported strong results for Q3 FY26, with Revenue from Operations at ₹ 450.3 crores and EBITDA at ₹ 71.1 crores

Registered YoY Revenue growth of 42.3% and EBITDA growth of 39.6%

Mumbai 23rd January 2026: Innova Captab Limited (BSE: 544067, NSE: INNOVACAP) is a leading pharmaceutical company committed to delivering high-quality healthcare solutions through a robust presence across the entire pharmaceuticals value chain, including research and development, manufacturing, distribution, marketing, and exports. The company is pleased to announce its financial results for the quarter and nine months ended December 31st, 2025.

Key Highlights

Q3 FY26 vs. Q3 FY25

- Revenue from Operations registered strong growth of 42% to ₹ 450.3 crores vs. ₹ 316.5 crores
- Recorded EBITDA growth of 40% to ₹ 71.1 crores vs. ₹ 50.9 crores. EBITDA margin for the quarter was ₹ 15.8%
- PAT for the quarter was ₹ 42.1 crores, registering growth of 23%. PAT margin was 9.4%

9M FY26 vs. 9M FY25

- Revenue from Operations for 9M FY26 cumulated to ₹ 1182.2 crores vs. ₹ 928.9 crores in 9M FY25 clocking growth of 27%
- EBITDA for 9M FY26 stood at 183.7 crores vs. ₹ 147.1 crores in 9M FY25, growing at 25%. EBITDA margin was 15.5%
- Profit after Tax was ₹ 102.8 crores. PAT margin came in at 8.7%

Commenting on the results, **Mr. Vinay Lohariwala, Managing Director – Innova Captab Limited** said “**Innova Captab Ltd delivered accelerated YoY revenue growth of 42% in Q3 FY26 and of 27% in 9M FY26. This strong performance underscores disciplined execution across our operations.**

This growth reflects improved client engagement in CDMO business and strategic geographic expansion in our Branded Generics vertical backed up by robust output across all our manufacturing facilities.

Following the successful inspection, we recently, also received Certificate of GMP Compliance from UK-MHRA for our Cephalosporin, Baddi unit and from PIC/s (SMDC, Ukraine) for Jammu facility. This is a testament of our adherence to global quality standards and will further expand our reach to the international markets.

Our key strategic initiatives are delivering tangible results, reinforcing our competitive edge and operational resilience. Both our business areas are well positioned to drive consistent, high-quality growth through FY26 and beyond. We remain committed to executing our long-term vision for stakeholder value creation.”

Financial Performance

(amount in ₹ crore except otherwise mentioned)

Q3 FY26 vs. Q3 FY25

Particulars	Q3 FY26	Q3 FY25	YoY Growth
Revenue from Operations	450.3	316.5	42.3%
EBITDA	71.1	50.9	39.6%
EBITDA Margin	15.8%	16.1%	(30 bps)
Profit after Tax	42.1	34.2	23.2%

9M FY26 vs. 9M FY25

Particulars	9M FY26	9M FY25	YoY Growth
Revenue from Operations	1182.2	928.9	27.3%
EBITDA	183.7	147.1	24.8%
EBITDA Margin (%)	15.5%	15.8%	(30 bps)
Profit after Tax	102.8	98.7	4.2%

About Innova Captab Limited

Innova Captab Limited {Innova} (BSE: 544067, NSE: INNOVACAP) is a leading pharmaceutical company in India with a comprehensive business model and presence across the pharmaceuticals value chain including research and development, manufacturing, drug distribution and marketing and exports. Through its Contract Development and Manufacturing Organization (CDMO) business, the company provides an elaborate suit of pharmaceutical products to over 300 clients in India and key international markets. Apart from this, the company has strong direct presence across India and international markets with its Branded Generics Business. The company operates five state-of-the-art manufacturing facilities consisting of 9 independent blocks, accredited by leading global regulatory bodies like WHO-GMP, EU-GMP, UK-MHRA, PIC/s among others.

For more details, please visit www.innovacaptab.com

For more information, please contact:

Mr. Lokesh Bhasin/ Mr. Ayush Kumar Garg

Email: investors@innovacaptab.com / ayush.garg@innovacaptab.com

DISCLAIMER:

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in the economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Innova Captab Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.